Products & Services · Total revenues
UPLIZNA — Total revenues
Amgen UPLIZNA — Total revenues increased by 187.9% to $262.00M in Q1 2026 compared to the prior quarter. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ1 2025
Last reportedQ1 2026
Rolls up toTotal Revenue
How to read this metric
Increasing revenues signal successful market penetration, strong physician adoption, and effective commercial execution, while declining revenues may indicate market saturation or competitive pressure.
Detailed definition
This metric captures the total gross sales generated from the commercialization of the specific therapeutic product with...
Peer comparison
Revenue performance for specialized therapeutics is typically benchmarked against peer products in the same disease category, with growth rates often compared to industry-wide specialty pharmacy trends.
Metric ID:
amgn_segment_uplizna_total_revenuesHistorical Data
2 periods
| Q1 '25 | Q1 '26 | |
|---|---|---|
| Value | $91.00M | $262.00M |
| QoQ Change | — | +187.9% |
| YoY Change | — | +187.9% |
Range$91.00M – $262.00M
Avg YoY Growth+187.9%
Median YoY Growth+187.9%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Amgen's uplizna — total revenues?
- Amgen (AMGN) reported uplizna — total revenues of $262.00M in Q1 2026.
- What does uplizna — total revenues mean?
- The total amount of money generated from sales of this specific drug during the period.